CBD for Tics, Tremors and Other Movement Disorders

Cannabis has been used for medicinal purposes for many years and, in recent decades, cannabidiol (CBD) has stood out for its beneficial properties for various conditions. Although the use of CBD in movement disorders is still under study, on the occasion of the upcoming World Movement Disorders Day we want to dedicate this article in which we explain what these disorders are, how they manifest themselves, their causes and the potential of the use of cannabis and CBD for their treatment.

Note: This is an informative article with no prescriptive character, it is not intended to prevent, diagnose or treat any disease. Its content can complement, but should never replace, the diagnosis or treatment of any disease or symptom. Cannactiva products are not medicines and are intended for external use. There may be new relevant scientific evidence since the date of publication. Consult with your physician before using CBD. The therapeutic approach must always be personalized and depends on the professional assessment.

What are movement disorders?

Movement disorders are involuntary movements resulting from neurological alterations in the central nervous system (1). These movements can affect different parts of the body and vary in their presentation and severity or intensity. Some of the most common movement disorders include dystonia, myoclonus, tremor, tics, and stereotypies (2). Each of these disorders has specific characteristics and different underlying causes.

Dystonia

Dystonia manifests itself in the form of involuntary muscle contractions that cause abnormal postures and repetitive movements. This condition can affect a single part of the body, known as focal dystonia; several parts of the body, called segmental dystonia; or the entire body, known as generalized dystonia. Dystonia can have a significant impact on patients’ quality of life, making everyday activities such as writing, walking or even speaking difficult (3).

Some causes: Genetic disorders, cerebral palsy, traumatic brain injury, among others.

Myoclonus

Myoclonias are involuntary, brief, rapid jerky movements. These movements can be positive or negative; positive myoclonus involves muscle contractions, while negative myoclonus relates to involuntary muscle relaxation. Myoclonias can be focal, affecting a specific area, or generalized, involving multiple areas of the body (4).

Some causes: Neurodegenerative diseases such as Alzheimer’s disease, dementia with Lewy bodies, epilepsy, among others.

Tremor

Tremors are oscillatory rhythmic movements that can be classified according to the position in which they occur. Types of tremor include postural tremor (when holding a position), resting tremor (when the body is relaxed), kinetic tremor (during movement), and isometric tremor (during muscle contraction without movement). Tremor can interfere with daily activities such as drinking from a glass or writing (3).

Some causes: They may be of genetic origin, especially in children. In adults, tremors are usually related to alterations in dopamine levels in the brain, as occurs in Parkinson’s disease or parkinsonism.

Tics

Tics are sudden, non-rhythmic, rapid movements, which may include vocalizations. These movements can be simple, such as blinking or jerking of the head, or complex, such as gestural movements or repeated phrases. Tics tend to worsen under conditions of exhaustion, anxiety, and emotional arousal, and can be a significant source of distress for sufferers (2).

Some causes: Tourette’s syndrome, transient or persistent motor disorders, neuropsychiatric conditions.

Stereotypies

Stereotypies are involuntary repetitive and rhythmic movements that serve no apparent purpose and may include complex movements such as body swaying, hand flapping, or facial grimacing. Although the exact causes are unknown, these movements are often triggered by factors such as stress, boredom, intense concentration and fatigue (2).

Some causes: Stereotypies may be present in autism spectrum conditions, developmental disorders, and other neuropsychiatric contexts.

Diseases with movement disorders

Movement disorders can originate from a variety of diseases, such as restless legs syndrome, essential tremor, Tourette’s syndrome, Parkinson’s disease and Huntington’s disease. Each of these conditions has unique characteristics and requires a specific treatment approach.

Traditional treatments for movement disorders, such as medications and surgical interventions, often provide limited relief and can have significant side effects. These side effects can demotivate patients and negatively affect their quality of life.

The pathophysiology of movement disorders is not completely understood. However, it is known that many of these diseases are triggered by imbalances in neurotransmitters, especially in the dopamine, GABA and glutamate systems.

Cannabinoids and Movement Disorders

THC (tetrahydrocannabinol) and CBD (cannabidiol) are two of the best known cannabinoids present in the cannabis plant. Both compounds interact with the body’s endocannabinoid system, a complex system that regulates various physiological processes, including modulation of neurotransmission, pain control and inflammation.

Cannabinoids and their implications in modulating neurotransmission could help balance brain chemistry, thereby reducing symptoms of movement disorders. This has been studied in animal models and in some clinical trials with mixed results.

In 1986, a case study evaluating the effectiveness of CBD for treating dystonia was published with promising results (5). This study was instrumental in initiating broader research on cannabinoids in the treatment of movement disorders.One of the first studies evaluating CBD for movement disorders did not report positive results (6). However, years later, it was found that THC could reduce symptoms of movement disorders, particularly in patients with Huntington’s disease (7, 8). These findings suggest that, although CBD may not be effective in all cases, other cannabinoids could offer therapeutic benefits.

The use of medical cannabis or marijuana (with THC) has been shown to significantly reduce tremors and other motor symptoms in patients with Parkinson’s disease (9, 10). Although CBD has not shown the same effects in all patients with movement disorders, its ability to improve quality of life through its anxiolytic and antidepressant effects is important (11).

Mechanisms of CBD to Improve Quality of Life

Although CBD can help reduce movement disorders in very specific cases, its main benefit lies in improving the emotional state of people living with these problems.

CBD can improve the quality of life of people with movement disorders through its sedative, anxiolytic, and antidepressant effects (12-16). These effects are related to the regulation of neurotransmission and modulation of the dopamine, GABA, and glutamate systems. By helping to restore balance in neurotransmitter activity, CBD may alleviate some of the symptoms associated with movement disorders.

In addition, CBD has beneficial potential for comorbidities associated with movement disorders due to its anti-inflammatory properties, preserving neuronal function and preventing the progression of underlying neurodegenerative processes in diseases such as Parkinson’s and Huntington’s disease.

CBD dosage to treat movement disorders

The only report that mentioned benefits of CBD to help dystonia used a dose of 100 to 600 mg of CBD per day for 6 weeks, as an adjunct to physician-prescribed medications. This range is broad and should not be taken as a guideline. Although CBD has an excellent safety profile, it is best to start with low doses and gradually increase them, always under professional supervision.

Drug interactions are an important consideration when undergoing medical treatment for movement disorders. It is crucial to keep in mind that CBD can interact with other medications, and side effects, which can include fatigue, diarrhea, and dizziness, should be carefully monitored.

Conclusion

CBD is a promising therapeutic agent that may improve the quality of life for people with movement disorders. Although other cannabinoids, such as THC, may be more effective in reducing the intensity of symptoms, CBD offers significant benefits in terms of emotional relief and overall well-being. Cannabinoids in movement disorders appear to be a very promising area of research, and their use should be carefully monitored by a healthcare professional to maximize benefits and minimize risks.

We hope this article has given you some guidance if you were looking for information about CBD and cannabis in this area of medicine. Please consult a professional for a personalized assessment and advice. This is a non-prescriptive informational article and is not intended to prevent, diagnose or treat any disease. Its content can complement, but should never replace, the diagnosis or treatment of any disease or symptom. Cannactiva products are not medicines and are intended for external use. There may be new relevant scientific evidence since the date of publication. Consult with your physician before using CBD. The therapeutic approach must always be personalized and depends on the professional assessment.

References

1. Harris, M. K., Shneyder, N., Borazanci, A., Korniychuk, E., Kelley, R. E., & Minagar, A. (2009). Movement disorders. The Medical clinics of North America, 93(2), 371-viii. https://doi.org/10.1016/j.mcna.2008.09.002
2. Wilson, R. B., & Keener, A. M. (2018). Movement Disorders in Children. Advances in pediatrics, 65(1), 229-240. https://doi.org/10.1016/j.yapd.2018.04.010
3. Sanger, T. D., Chen, D., Fehlings, D. L., Hallett, M., Lang, A. E., Mink, J. W., Singer, H. S., Alter, K., Ben-Pazi, H., Butler, E. E., E. E., Chen, R., Collins, A.., Dayanidhi, S., Forssberg, H., Fowler, E., Gilbert, D. L., Gorman, S. L., Gormley, M. E., Jr, Dayanidhi, S., Forssberg, H., Fowler, E., Gilbert, D. L., Gorman, S. L., Gormley, M. E., Jr, Jinnah, H. A., Kornblau, B., … Valero-Cuevas, F. (2010). Definition and classification of hyperkinetic movements in childhood. Movement disorders : official journal of the Movement Disorder Society, 25(11), 1538-1549. https://doi.org/10.1002/mds.23088
4. Burton, Matthew & Dalrymple, W & Figari, Renzo (2022). Assessment and Treatment of Myoclonus: A Review. Neurology. 18. 38. http://dx.doi.org/10.17925/USN.2022.18.1.38
5. Consroe, P., Sandyk, R., & Snider, S. R. (1986). Open label evaluation of cannabidiol in dystonic movement disorders. International Journal of Neuroscience, 30(4), 277-282. https://doi.org/10.3109/00207458608985678
6. Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., & Schram, K. (1991). Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacology, biochemistry, and behavior, 40(3), 701-708. https://doi.org/10.1016/0091-3057(91)90386-g
7. Curtis, A., & Rickards, H. (2006). Nabilone could treat chorea and irritability in Huntington’s disease. The Journal of neuropsychiatry and clinical neurosciences, 18(4), 553-554. https://doi.org/10.1176/jnp.2006.18.4.553
8. Curtis, A., Mitchell, I., Patel, S., Ives, N., & Rickards, H. (2009). A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Movement disorders : official journal of the Movement Disorder Society, 24(15), 2254-2259. https://doi.org/10.1002/mds.22809
9. Venderová, K., Růzicka, E., Vorísek, V., & Visnovský, P. (2004). Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms. Movement disorders : official journal of the Movement Disorder Society, 19(9), 1102-1106. https://doi.org/10.1002/mds.20111
10. Lotan, I., Treves, T. A., Roditi, Y., & Djaldetti, R. (2014). Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clinical neuropharmacology, 37(2), 41-44 . https://doi.org/10.1097/WNF.0000000000000016.
11. Chagas, M. H., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E., & Crippa, J. A. (2014). Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. Journal of psychopharmacology (Oxford, England), 28(11), 1088-1098. https://doi.org/10.1177/0269881114550355
12. Chagas, M. H., Crippa, J. A., Zuardi, A. W., Hallak, J. E., Machado-de-Sousa, J. P., Hirotsu, C., Maia, L., Tufik, S., & Andersen, M. L. (2013). Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. Journal of psychopharmacology (Oxford, England), 27(3), 312-316. https://doi.org/10.1177/0269881112474524
13. Crippa, J. A., Zuardi, A. W., Martin-Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar-Poli, P. (2009). Cannabis and anxiety: a critical review of the evidence. Human psychopharmacology, 24(7), 515-523 . https://doi.org/10.1002/hup.1048.
14. Bergamaschi, M. M. M., Queiroz, R. H., Chagas, M. H., de Oliveira, D. C., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., Martín-Santos, R., Hallak, J. E., Zuardi, A. W., & Crippa, J. A. (2011). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 36(6), 1219-1226. https://doi.org/10.1038/npp.2011.6
15. Saito, V. M., Wotjak, C. T., & Moreira, F. A. (2010). Exploração farmacológica do sistema endocanabinoide: novas perspectivas para o tratamento de transtornos de ansiedade e depressão? [Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?] Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), 32 Suppl 1, S7-S14.
16. Zanelati, T. V., Biojone, C., Moreira, F. A., Guimarães, F. S., & Joca, S. R. (2010). Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. British journal of pharmacology, 159(1), 122-128. https://doi.org/10.1111/j.1476-5381.2009.00521.x